Abstract:Background. The application of potent immunosuppressants has decreased the incidence of acute rejection and increased short- and long-term graft survival; however, these drugs cause a variety of complications. In China, many transplant centers have adopted the immunosuppressive protocols based on the white population, neglecting the differences between the races. The purpose of this study was to explore a suitable immunosuppressive regimen for Chinese renal allograft recipients.Methods. Two hundred cadaveric renal allograft recipients who underwent transplantation between July 1999 and October 2001 were observed. Before October 2000, 104 recipients received the conventional dose of immunosuppressants; thereafter, 96 recipients received lower dose treatment. Doses of immunosuppressive agents, the incidence of acute rejection and pulmonary infection, and patient and graft survival rates were compared between the two groups.Results. Doses of mycophenolate mofetil (MMF) and cyclosporine A (CsA) administered in the conventional dose group were significantly higher than in the lower dose group at 3 months posttransplant, as was prednisone at 6 months posttransplant. The incidence of acute rejection and subclinical rejection that was biopsy-proven or diagnosed by clinical manifestations was 17.3% and 19.8%, respectively, in the conventional dose group and the lower dose group within the first 6 months, and no significant difference was noted (P=0.55). The incidence of pulmonary infection, especially severe infection, was much higher in the conventional treatment group (40.1% and 26.9%, respectively) than that in the lower dose group (11.5% and 5.2%, respectively), and the differences were statistically significant (P<0.001). The corresponding 1-year survival rate of patients was 87.4% and 97.9% (P<0.01), and that of renal grafts was 85.5% and 96.9% (P<0.01), for patients receiving conventional dose and lower dose immunosuppressive drugs, respectively. The rate of death with a functioning allograft caused by infection in the conventional dose group was significantly higher than that in the lower dose group (12.5% vs. 0%, P<0.01).Conclusions. The regimen of lower dose MMF, CsA, and prednisone in combination can significantly reduce the incidence of pulmonary infection, especially severe pulmonary infection, without increasing the incidence and severity of allograft rejection.

Clinical Research of FK506 Therapeutic Window Concentration in Renal Transplant Recipients

Preliminary Clinical Research of FK506 Therapeutic Windows Trough Concentration in Chinese Heart Transplantation Recipients

CLINICAL INVESTIGATION ON THE THERAPEUTIC WINDOW CONCENTRATION OF FK506 IN RENAL ALLO-GRAFF RFIPIENTS

Pharmacokinetic and Clinical Study of FK506

Clinical Application of FK506 in Renal Transplantation

Clinical Study on the Use of FK506 after Renal Transplantation

Effect of Switch from Cyclosporine to FK506 on Renal Graft Outcome in Patients after Initial Acute Rejection

The Comparison of Two Immunosuppression Schemes Containing Tacrolimus in Renal Transplant Recipients

Clinical effect of FK506 on the treatment of steroid-resistant rejection after kidney transplantation

Correlation analysis of FK506 blood concentration with liver function index in renal transplant recipients

Long-term Evaluation of FK506 Based Immunosuppressive Therapy in Kidney Transplantation

Clinical Analysis of 2520 Renal Transplantations in One Center

Clinical Research on Safety of Different Concentrations of FK506 for Patients Underging Living Donor Liver Transplantation: a Report of 46 Cases

CLINICAL USE OF FK506 AS PRIMARY ANTI-REJECTION AGENT IN RENAL ALLOGRAFT RECIPEINTS

Improved Clinical Outcomes in Chinese Renal Allograft Recipients Receiving Lower Dose Immunosuppressants

The Prospective Randomized Study on Prevention of Cadaveric Renal Allograft Rejection by Tacrolimus (FK506)

A Clinical Research of Taerolimus (prograf) in the Prevention of Renal Allograft Rejection:A Report of 136 Cases

Application of Tacrolimus in 862 Renal Transplantation Recipients

The Use of Tacrolimus in 932 Renal Transplant Recipients

Replacement Proposals of FK506 in Patients Having Creeping Serum Creatinine after Renal Transplantation

Electrospun Polymer Fibers Modified with FK506 for the Long-Term Treatment of Acute Cardiac Allograft Rejection in a Heart Transplantation Model.